SUMMIT THERAPEUTICS INC (SMMT)
US86627T1088 - Common Stock
Taking everything into account, SMMT scores 3 out of 10 in our fundamental rating. SMMT was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SMMT as it has an excellent financial health rating, but there are worries on the profitability. SMMT has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year SMMT has reported negative net income.
SMMT had a negative operating cash flow in the past year.
In the past 5 years SMMT reported 4 times negative net income.
SMMT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -122.29%, SMMT is doing worse than 80.18% of the companies in the same industry.
SMMT has a Return On Equity of -140.42%. This is in the lower half of the industry: SMMT underperforms 63.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -122.29% | ||
| ROE | -140.42% | ||
| ROIC | N/A |
ROA(3y)-131%
ROA(5y)-86.39%
ROE(3y)-320.01%
ROE(5y)-201.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SMMT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SMMT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SMMT has more shares outstanding
The number of shares outstanding for SMMT has been increased compared to 5 years ago.
The debt/assets ratio for SMMT has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 110.69 indicates that SMMT is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 110.69, SMMT belongs to the best of the industry, outperforming 99.82% of the companies in the same industry.
SMMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 110.69 |
ROIC/WACCN/A
WACC10.76%
2.3 Liquidity
SMMT has a Current Ratio of 8.31. This indicates that SMMT is financially healthy and has no problem in meeting its short term obligations.
SMMT's Current ratio of 8.31 is fine compared to the rest of the industry. SMMT outperforms 73.27% of its industry peers.
SMMT has a Quick Ratio of 8.31. This indicates that SMMT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SMMT (8.31) is better than 73.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.31 | ||
| Quick Ratio | 8.31 |
3. Growth
3.1 Past
The earnings per share for SMMT have decreased strongly by -50.00% in the last year.
Looking at the last year, SMMT shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-166.67%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to grow by 36.90% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-98.22%
EPS Next 2Y-67.24%
EPS Next 3Y-59.88%
EPS Next 5Y36.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
SMMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SMMT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SMMT's earnings are expected to decrease with -59.88% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-67.24%
EPS Next 3Y-59.88%
5. Dividend
5.1 Amount
No dividends for SMMT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SUMMIT THERAPEUTICS INC
NASDAQ:SMMT (1/14/2025, 8:05:55 PM)
Premarket: 16.71 +0.06 (+0.36%)16.65
-1.53 (-8.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners10.1%
Inst Owner Change0%
Ins Owners84.57%
Ins Owner Change0.61%
Market Cap12.28B
Analysts83.33
Price Target34 (104.2%)
Short Float %17.29%
Short Ratio9.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.98%
Min EPS beat(2)-42.31%
Max EPS beat(2)-17.64%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.08%
PT rev (3m)12.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-18.85%
EPS NY rev (1m)3.56%
EPS NY rev (3m)-6.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 28.04 | ||
| P/tB | 28.17 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS0.59
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -122.29% | ||
| ROE | -140.42% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-131%
ROA(5y)-86.39%
ROE(3y)-320.01%
ROE(5y)-201.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 130.93% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.31 | ||
| Quick Ratio | 8.31 | ||
| Altman-Z | 110.69 |
F-Score6
WACC10.76%
ROIC/WACCN/A
Cap/Depr(3y)45.61%
Cap/Depr(5y)34.59%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-166.67%
EPS Next Y-98.22%
EPS Next 2Y-67.24%
EPS Next 3Y-59.88%
EPS Next 5Y36.9%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-39.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.44%
EBIT Next 3Y-52.07%
EBIT Next 5YN/A
FCF growth 1Y-99.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.77%
OCF growth 3YN/A
OCF growth 5YN/A